Climb Bio Overview
- Year Founded
-
2018
- Status
-
Public
- Employees
-
18
- Stock Symbol
-
CLYM
- Investments
-
3
- Share Price
-
$1.27
- (As of Friday Closing)
Climb Bio General Information
Description
Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. its product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has the potential to treat a broad range of B-cell-mediated diseases.
Contact Information
Website
www.climbbio.comCorporate Office
- 20 William Street
- Suite 145
- Wellesley Hills, MA 02481
- United States
Corporate Office
- 20 William Street
- Suite 145
- Wellesley Hills, MA 02481
- United States
Climb Bio Timeline
Climb Bio Stock Performance
As of 25-Apr-2025, Climb Bio’s stock price is $1.27. Its current market cap is $87.7M with 67.5M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.27 | $1.30 | $1.05 - $11.55 | $87.7M | 67.5M | 257K | -$1.53 |
Climb Bio Financials Summary
As of 31-Dec-2024, Climb Bio has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 31-Dec-2024 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
|---|---|---|---|---|
| EV | (72,290) | (72,290) | (32,528) | (24,545) |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (82,029) | (82,029) | (39,739) | (46,619) |
| Net Income | (73,897) | (73,897) | (35,119) | (45,244) |
| Total Assets | 217,187 | 217,187 | 110,469 | 134,992 |
| Total Debt | 532 | 532 | 349 | 480 |
Climb Bio Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Climb Bio Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Climb Bio Comparisons
Industry
Financing
Details
Climb Bio Competitors (6)
One of Climb Bio’s 6 competitors is Biohaven, a Formerly VC-backed company based in Tortola, VI.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Biohaven | Formerly VC-backed | Tortola, VI | ||||
| Neurona Therapeutics | Venture Capital-Backed | South San Francisco, CA | ||||
| IPI Legacy Liquidation | Formerly VC-backed | Seattle, WA | ||||
| Autobahn Therapeutics | Venture Capital-Backed | San Diego, CA | ||||
| ACADIA Pharmaceuticals | Formerly VC-backed | San Diego, CA |
Climb Bio Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Climb Bio Patents
Climb Bio Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| GB-202213780-D0 | Novel compounds and process | Inactive | 21-Sep-2022 | ||
| GB-202211682-D0 | Novel compounds | Inactive | 10-Aug-2022 | ||
| GB-202103884-D0 | Novel process | Inactive | 19-Mar-2021 | ||
| US-20220296613-A1 | Food-independent dosing of cv-10155 to treat gabaa disorders | Inactive | 19-Mar-2021 | ||
| US-20220296614-A1 | Dosing of cv-10155 in the evening or prior to sleep to treat gabaa disorders | Inactive | 19-Mar-2021 | A61K31/58 |
Climb Bio Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Climb Bio Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Climb Bio Investments & Acquisitions (3)
Climb Bio’s most recent deal was a Merger/Acquisition with Tenet Medicines for . The deal was made on 27-Jun-2024.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Tenet Medicines | 27-Jun-2024 | Merger/Acquisition | Biotechnology | ||
| Athenen Therapeutics | 15-Oct-2020 | Merger/Acquisition | Therapeutic Devices | ||
| Canot (IPR&D Assets) | 01-Feb-2019 | Corporate Asset Purchase | Buildings and Property |
Climb Bio ESG
Risk Overview
Risk Rating
Updated April, 01, 2022
34.67 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,912
Rank
Percentile
Pharmaceuticals
Industry
of 965
Rank
Percentile
Biotechnology
Subindustry
of 443
Rank
Percentile
Climb Bio FAQs
-
When was Climb Bio founded?
Climb Bio was founded in 2018.
-
Where is Climb Bio headquartered?
Climb Bio is headquartered in Wellesley Hills, MA.
-
What is the size of Climb Bio?
Climb Bio has 18 total employees.
-
What industry is Climb Bio in?
Climb Bio’s primary industry is Drug Discovery.
-
Is Climb Bio a private or public company?
Climb Bio is a Public company.
-
What is Climb Bio’s stock symbol?
The ticker symbol for Climb Bio is CLYM.
-
What is the current stock price of Climb Bio?
As of 25-Apr-2025 the stock price of Climb Bio is $1.27.
-
What is the current market cap of Climb Bio?
The current market capitalization of Climb Bio is $87.7M.
-
Who are Climb Bio’s competitors?
Biohaven, Neurona Therapeutics, IPI Legacy Liquidation, Autobahn Therapeutics, and ACADIA Pharmaceuticals are some of the 6 competitors of Climb Bio.
-
What is Climb Bio’s annual earnings per share (EPS)?
Climb Bio’s EPS for 12 months was -$1.53.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
